AstraZeneca is a global biopharmaceutical company formed in 1999 through the merger of the Swedish firm Astra and the British company Zeneca. The company's operations are concentrated in oncology, biopharmaceuticals, respiratory, and rare diseases. Its core activities encompass the research, development, and commercialization of prescription medicines, supported by annual R&D investment running into the billions of dollars.
The firm's commercial portfolio includes 16 medicines classified as blockbusters by revenue. Its R&D pipeline comprises 197 projects, with the stated goal of delivering 20 new medicines to patients by the end of 2030. Technical domains of focus include data science, artificial intelligence, and cell therapies.
AstraZeneca maintains a significant global footprint, with major research and development hubs in Cambridge, UK; Gothenburg, Sweden; Gaithersburg and Boston, USA; and Shanghai and Beijing, China. The company's culture is defined by a stated commitment to following the science and putting patients first, values shaped by its foundational merger.
